


<b>PRODUCT NAME</b>	<b>Recombinant Rat NGAL</b> <b>Recombinant protein</b>
<b>PRODUCT NO.</b>	<b>SP003RA</b>
<b>PRESENTATION</b>	Production: E. coli Source: Full length amino acid sequence Content: 1 mL, 400 pg/mL +/- 15% Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl, 0.5% BSA; 0.5% Tween 20; 0.0016% Phenol red; 0.1% Proclin 950 Storage: 2-8°C

**PREPARATION** This product is purified full length recombinant protein without any tags, produced from E. coli

**APPLICATION** **ELISA**  
This antigen is well suited as a standard in NGAL quantifying assays, such as e.g. ELISA.

The figure illustrates the calibration curve of a sandwich assay with ABS 039-15 as the capture antibody and ABS 039-32B as the biotinylated detection antibody.



**BACKGROUND** Rat NGAL, so called because it is the ortholog of human neutrophil gelatinase-associated lipocalin (NGAL), is also called lipocalin-2, 25-kDa alpha 2-microglobulin-related protein or neutrophil-related lipocalin. It is expressed by neutrophils and various epithelial cells, including cells tubular cells of the kidney. It is involved in physiological processes such as the binding of siderophore iron and tissue growth and regeneration. It is up-regulated in a variety of pathological situations including infection, inflammation, renal injury and certain adenocarcinomas.

**REFERENCES**

- Mishra J et al (2003) Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534-43.
- Zhang J et al (2009) NGAL Expression in Kidney of Spontaneously Hypertensive Rats (SHR) Treated with Doxorubicin (DXR) Alone or Combined with Dexrazoxane (DRZ) (Presented at Tox Expo 2009)
- Adler M et al (2010) Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicology Letters 196:1-11.

**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.